Abstract: The serotonin (5-HT) syndrome occurs in humans after antidepressant overdose or a combination of drugs inducing a massive increase of extracellular 5-HT. Several 5-HT receptors participate in the expression of this syndrome in humans and animal models. Likewise, the 5-HT2B receptor has been proposed as a positive modulator of serotonergic activity, but whether it is involved in the expression of the 5-HT syndrome has not yet been studied. We analyzed thus, the putative role of the 5-HT2B receptor in the development of this disorder by the forced swimming test (FST) and behavioural assessment in the open field. In the FST, the genetic or pharmacological ablation of the 5-HT2B receptor facilitated the selective serotonin reuptake inhibitors (SSRI)-induced expression of symptoms related to the 5-HT syndrome like increase of immobility time, hind limb abduction and Straub tail. Similar responses were developed in the FST by both wild type (WT) and 5-HT2B-/-mice after the administration of 5-HT1A, 5-HT2A and 5-HT2C receptors agonists. In contrast, the 5-HT2B and 5-HT1B receptors agonists decreased immobility time. The SSRIs-induced 5-HT syndrome was blocked in both WT and 5-HT2B-/-mice by administration of 5-HT1A and 5-HT2C receptors antagonists. We then performed a behavioral characterization and confirmed that 5-HT2B-/-mice were more prone to develop the 5-HT syndrome symptoms after administration of high doses of SSRIs or the 5-HT precursor. These evidences suggest that the presence of 5-HT2B receptor hinders acute 5-HT toxicity once high levels of 5-HT are attained. Therefore, differential agonism/antagonism of these receptors should be considered in the search of therapeutic targets for treating this serious disorder. 
INTRODUCTION
The serotonin (5-HT) syndrome is a serious disorder reported in humans that most commonly appears after antidepressant overdose or after combining several psychotropic medications (Kalueff et al., 2008) . The exaggerated serotonergic function induced by these conditions can be simulated in experimental animals by the administration of serotonin-enhanced drugs like 5-HT precursors or 5-HT receptors agonists (Kalueff et al., 2008; Van Oekelen et al., 2002) .
Thus, signs of the 5-HT syndrome are possibly due to a huge increase of extracellular 5-HT activating 5-HT 1A , 5-HT 2C , 5-HT 2A , and 5-HT 7 receptors among others (Cryan & Lucki, 2000; Van Oekelen et al., 2002; Landry et al. 2006; Fox et al., 2008) . This acute 5-HT toxicity has been characterized in mice by the expression of certain behavioral and physiological responses as hind limb abduction, forepaw treading, backward movement, Straub tail, head weaving, tremor and low flat posture (Izumi et al., 2006; Kennett et al., 1985; Sternbach et al, 1991; Fox et al., 2007) .
The forced swimming test (FST) is the behavioural paradigm most employed for screening new molecules potentially efficacious as antidepressants. A highly heterogeneous sensitivity to antidepressants effects and particularly to selective 5-HT reuptake inhibitors (SSRI), among several strains of mice was clearly demonstrated in the FST (Lucki et al. 2001; David et al., 2003) . This fact suggests a fine genetic-dependent regulation in the components of the 5-HT neurotransmission systems involved in antidepressants effects. In particular, one of the signs of the 5-HT syndrome, the hind limb abduction was shown specifically by 129/Sv mice in the FST at high dose of SSRIs (Lucki et al., 2001) . As for the 5-HT syndrome, many subtypes of 5-HT receptors have been proposed as regulating the response in the FST either acting at the presynaptic membrane (Bortolozzi et al., 2004; Jones and Lucki, 2005) or at a postsynaptical level (Cryan and Lucki, 2000; Boothman et al., 2003; Tatarczyńska et al., 2005; Cremers et al., 2007) . For instance, the 5-HT 2B/2C receptor agonists WAY 161503, Ro 60-0175 and Ro 60-0332 all decrease immobility time in rats in the FST, whereas the non-selective 5-HT 2 receptors agonist m-CPP increases immobility scores (Cryan et al., 2000) . These results implicate 5-HT 2B and/or 5-HT 2C receptors in the behavioural effects of antidepressants, but it has been difficult to dissect the role of each receptor subtype given that non-selective drugs were employed in most of these studies. We have recently observed that stimulation of 5-HT 2B receptors in mice induced an antidepressant-like effect in the FST (unpublished personal data).
Taking these evidences into account, we investigated here a putative participation of 5-HT 2B receptors in the expression of the 5-HT syndrome, and revealed that this 5-HT receptor has a impeding role in the development of this syndrome.
MATERIALS AND METHODS

Animals
5-HT 2B
-/-mice used in these experiments are in a pure 129/SvPAS background, while SERT -/-mice used have a pure C57Bl/6NCrl background. Adult (7-9 week-old) male and female 5HT 2B
-/-, SERT -/-and their respective wild type (WT) control mice (originally obtained at Charles River Laboratories, L'Arbresle France) were bred at our animal facilities. All mice were maintained on a 12 light: 12 dark schedule (lights on at 8:00) and housed in groups of 3-5 of the same sex and genetic background according to the EC directive 86/609/CEE. Food and water were provided ad libitum. Behavioural studies were carried out in the afternoon (14:00-20:00). Mice were moved to the testing room in their home cage at least 5 days prior to testing to allow for habituation to the environment.
Forced Swimming Test
Mice were randomly assigned to the different experimental groups receiving various drug treatments or vehicle. Mice FST was conducted essentially as described by Lucki et al, (2001) .
Briefly, swim sessions were conducted by placing mice individually in a plastic cylinder (26 cm tall × 17 cm in diameter) filled with water (24-26°C) to a depth of 15 cm. The depth was deep enough so that mice could not support themselves by placing their paws or tail on the base of the cylinder. Standard 6-min test duration was employed, and immobility time was only measured during the last 4 minutes of the test period. Mice were judged to be immobile when no additional activity was observed other than that required to keep their head above the water. After removing mice from water, they were dried and placed in their home cage. Each animal was challenged once. The observer was blind to the experimental conditions being measured.
Injections were administered 30 minutes before the test session. In those experiments where two drugs were studied, the injections were administered 45 (i.e., an antagonist) and 30 minutes before the test session.
Serotonin Syndrome assessment
Experiments were conducted in an open field, consisting of a Plexiglass box (20 x 40 x 15cm).
Each animal was challenged once. Fifteen minutes after the injection, mice were placed in one of the corners of the box. Postures and behaviours associated with the rodent 5-HT syndrome (Kalueff et al., 2008; Fox et al., 2007) were recorded for five 1-min periods every 5 min. In each assessment period the acts and postures evaluated were the following: intermittent behaviours including backward gait, tics, tremor and hunched back were scored on a scale of 0 to 4: 0, absent; 1, expressed once; 2, expressed several times; 3, permanently expressed; for continuous behaviors including flat body position, piloerection, Straub tail and hind leg abduction, a value of 1 was assigned each time that they were present. In order to summarize the results obtained, a global score was calculated individually for each mouse by adding each of the five 1-min periods for each sign. Behaviour assessment was performed by an observer blind to both genotype and treatment. and a coulometric detector (Coulochem III; ESA Inc., Chelmsford, USA) with a 5011 analytical cell to quantify 5-HT. The first electrode was fixed at -100 mV and the second electrode at +300 mV. The gain of the detector was set at 50 nA. The signal of the second electrode was connected to an HP Chemstation for HPLC. The composition of the mobile phase was 50 mM NaH2PO4, 0.1 mM Na2EDTA, 0.65 mM octyl sodium sulphate and 14% (v ⁄ v) methanol, pH 3.5. The flow rate was set at 1 ml ⁄ min.
Plasmatic 5-HT determination
Statistical analysis
To determine differences between the experimental groups, behavioural parameters (immobility times in the FST; score in the 5-HT syndrome) and 5-HT plasma levels were analyzed by either a single-factor or a two-factor analysis of variance (ANOVA) 
Evaluation of putative contribution of 5-HT 1B receptors in the FST
A significant decrease of immobility time was measured in WT mice treated with the selective 5-HT 1B receptor agonist CGS12066A at 2 mg/kg (Fig 2.A) . This effect was blocked by pretreating animals with the selective 5-HT 1B receptor antagonist SB216641 at 0.5 mg/kg (a dose that did not modify the basal response of mice in the FST). Interestingly, CGS12066A
also induced a significant decrease of immobility time in 5-HT 2B -/-mice, effect blocked by pretreatment with SB216641. These results imply that the 5-HT 1B receptor is involved in the response in the FST as previously reported, and this role does not depend on the presence of 5-HT 2B receptors.
Evaluation of the contribution of 5-HT 1A receptors in the FST
WT and 5-HT 2B -/-mice treated with the selective 5-HT 1A receptor agonist 8-OH-DPAT at 5 mg/kg presented increased immobility time (Fig 2.B) , hind limb abduction and Straub tail, as it was the case of mice receiving high doses of SSRIs. Further, the selective 5-HT 1A receptor antagonist WAY100635 at 0.5 mg/kg (a dose that did not modify the basal performance of neither genotype in the FST) prevented the increase in immobility time induced by 8-OH-DPAT in WT as well as in 5-HT 2B -/-mice.
Evaluation of the contribution of 5-HT 2C receptor in the FST
WT and 5-HT 2B -/-mice treated with the preferential 5-HT 2C receptor agonist WAY161503 at 5 mg/kg presented increased immobility time (Fig 3.C) , hind limb abduction and Straub tail, as it was the case of mice receiving high SSRI doses and the 5-HT 1A receptor agonist. Further, blockade of the 5-HT 2C receptor by SB242084 at 0.5 mg/kg prevented the WAY161503-induced increase in immobility time in WT as well as in 5-HT 2B -/-mice.
Evaluation of the contribution of 5-HT 2A receptor in the FST
WT and 5-HT 2B -/-mice treated with the non selective 5-HT 2 agonist DOI at 1 mg/kg presented increased immobility time (Fig 2.D) , hind limb abduction and Straub tail. In this case, the selective 5-HT 2A antagonist MDL100907 at 0.5 mg/kg significantly blocked the effect induced by DOI in WT mice, but the reduction in 5-HT 2B -/-mice did not reach statistical significance.
Behavioural characterization of the serotonin syndrome
In order to confirm that the signs observed in the FST in mice treated with high doses of SSRIs or certain 5-HT receptors agonists corresponded to a 5-HT syndrome, we characterized its behavioral expression in our experimental conditions by first evaluating it in SERT -/-mice treated with the 5-HT precursor 5-hydroxytryptophane (5-HTP). The absence of SERT makes these mice more prone to develop a 5-HT syndrome (Fox et al., 2007) and we confirmed this finding in our paradigm (Suppl Fig 2) . We then studied the 5-HTP-induced 5-HT syndrome in 129/SvPAS and 5-HT 2B -/-mice. A significant increase in the syndrome score (see methods)
was observed in 5-HT 2B -/-mice but not in WT mice receiving 5-HTP at 50 mg/kg, (Fig 3.A) .
After receiving 5-HTP at 100 mg/kg mice of either genotype showed a significant increase in the score, much higher in mutant mice. Then, and according to the Flx dose-response curve obtained in each genotype Flx 3 and 30 mg/kg was administered to WT mice, and Flx 3 and 20 mg/kg to 5-HT 2B -/-mice and demonstrated that high doses of SSRI can induce a 5-HT syndrome in WT as well as in 5-HT 2B -/-mice ( Fig 3A) .
To further study the role of the 5-HT 2B receptor, WT mice pretreated with the selective 5-HT 2B
receptor antagonist RS127445 at 0.5 mg/kg received 5-HTP 50 mg/kg or Flx 20 mg/kg (Fig   3.B) , but in opposition to 5-HT 2B -/-mice, the score was not significantly different from vehicletreated mice. 
Attenuation of the Serotonin Syndrome in the FST
Determination of plasmatic 5-HT levels
The sensibility to develop the 5-HT syndrome in either genotype at different doses of SSRIs could be due to differences in the increase of extracellular serotonin sufficient to activate several receptors mediating this syndrome. Accordingly, plasmatic 5-HT levels were measured after SSRIs administration in WT and 5-HT 2B -/-mice (Fig 4) . No significant differences were observed between genotypes in the 5-HT plasmatic levels attained after each treatment. Additionally, previous data confirmed that selective 5-HT 2C receptor antagonists are able to potentiate SSRI-induced extracellular 5-HT elevation (Cremers et al., 2004 (Cremers et al., , 2007 , but have no effect on extracellular serotonin levels when administered alone. Besides, no behavioural per se effect of 5-HT 2C antagonists has been described (Cremers et al, 2004; Cryan & Lucki, 2000; Bristow et al., 2000; Dhonnchadha et al., 2005) , consistent with the lack of effect of SB242084 mice at 100 mg/kg. ** p <0.01; *** p <0.001 comparing to Veh-treated groups; data are expressed as mean ± SEM (n = 4 mice for each group).
